Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia
Referencias
Additional references
Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007102.pub2]
Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38(3):1373‐85.
Chan Lee, Harriet O Smith, Seung J Kim. Epidemiology. Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009:49‐96.
Covens A, Fialici VL, Burger RA, Osborne R, Chen MD. Phase II trial of pulse dactinomycin as salvage therapy for failed low‐risk gestational trophoblastic neoplasia. Cancer 2006;107(6):1280‐6.
Common Terminology Criteria for Adverse Events (CTCAE). http/ctep/cancer.gov.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.
Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first‐line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second‐line therapy for low risk disease. British Journal of Cancer 2000;82:1547‐52.
El‐Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High‐dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. British Journal of Cancer 2005;93:620‐1.
El‐Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncology 2007;8(8):715‐24.
Fisher R. Genetics. In: BW Hancock, M Seckl, RS Berkowitz, LA Cole editor(s). Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009.
Hammond CB, Borchert LG, Tyrey L, Creaman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics and Gynecology 1973;115(4):451‐7.
Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. Journal of Reproductive Medicine 2006;51:764‐6.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Homeseley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology 1988;72(3):413‐8.
Khan F, Everard J, Ahmed S, Coleman RE, Aitkin M, Hancock BW. Low‐risk persistent trophoblastic disease treated with low‐dose methotrexate: efficacy, acute and long term effects. British Journal of Cancer 2003;89(12):2197‐201.
Kohorn EI, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, et al. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committeeo the International Society for the Study of Trophoblastic Disease and International Gynecologic Cancer Society. International Journal of Gynecological Cancer 2000;10:84‐8.
Lurain J, Nejad B. Secondary chemotherapy for high‐risk gestational trophoblastic neoplasia. Gynecologic Oncology 2005;97:618‐23.
Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, et al. Relapse rate of patients with low‐risk gestational trophoblastic tumor initially treated with single‐agent chemotherapy. Gynecologic Oncology 2005;96:616‐20.
McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low‐risk persistent gestational trophoblastic disease: outcome after initial treatment with low‐dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology 2002;20(7):1838‐44.
Nagan HY. The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics 2002;77:285‐7.
Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high‐risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 2000;18:854‐9.
JR Palmer. Advances in the epidemiology of gestational trophoblastic disease. Journal of Reproductive Medicine 1994;39(3):155‐62.
Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. British Journal of Obstetrics and Gynaecology 2002;109:99‐102.
Seckl MJ. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom. In: BW Hancock, M Seckl, RS Berkowitz, LA Cole editor(s). Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009.
Tham BW, Everard JE, Tidy JA, Drew D, Hancock BW. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. British Journal of Obstetrics and Gynaecology 2003;110(6):555‐9.
Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Salvage chemotherapy of relapsed or high‐risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Annals of Oncology 2008;19:1578‐3.
WHO. Gestatational trophoblastic diseases. WHO Technical report Sens 6921983.
